Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit
Kaleido Biosciences (Nasdaq: KLDO) will have CEO Dan Menichella present a company overview at the Jefferies Virtual Next Generation IBD Therapeutics Summit on October 19, 2021, at 1:45 PM ET. This presentation will focus on the company's innovative approach to treating inflammatory diseases through microbiome modulation. Investors can access the live webcast and an archived replay for 30 days on the company’s website. Kaleido leverages a proprietary platform for discovering Microbiome Metabolic Therapies aimed at addressing unmet patient needs in various diseases.
- None.
- None.
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that CEO Dan Menichella will present a company overview at the Jefferies Virtual Next Generation IBD Therapeutics Summit at 1:45PM ET on Tuesday, October 19.
The webcast of the presentation will be made available in the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be available for 30 days following the event.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Contacts:
Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com
Investors and Media
Kotaro Yoshida
Argot Partners
212-600-1902
kaleido@argotpartners.com
FAQ
What is the date and time of Kaleido Biosciences' CEO presentation?
Where can I watch the Kaleido Biosciences presentation?
What is the focus of Kaleido Biosciences at the summit?
How long will the archived replay of the presentation be available?
What is Kaleido Biosciences' stock symbol?
